|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,872.50 GBX | -0.72% |
|
+0.75% | +2.63% |
| 05-14 | Morningstar Upgrades GSK to Buy Rating | MT |
| 05-14 | UK Stocks-Factors to watch on May 14 | RE |
| Capitalization | 74.75B 101B 86.33B 78.94B 138B 9,635B 140B 942B 366B 4,578B 378B 370B 15,936B | P/E ratio 2026 * |
11.8x | P/E ratio 2027 * | 11x |
|---|---|---|---|---|---|
| Enterprise value | 87.03B 117B 101B 91.91B 161B 11,219B 162B 1,097B 426B 5,331B 440B 431B 18,555B | EV / Sales 2026 * |
2.58x | EV / Sales 2027 * | 2.38x |
| Free-Float |
92.31% | Yield 2026 * |
3.73% | Yield 2027 * | 3.91% |
Last Transcript: GSK plc
| 1 day | -0.72% | ||
| 1 week | +0.75% | ||
| Current month | -2.90% | ||
| 1 month | -14.50% | ||
| 3 months | -13.51% | ||
| 6 months | +4.96% | ||
| Current year | +2.63% |
| 1 week | 1,822 |  | 1,897.5 |
| 1 month | 1,822 | | 2,156 |
| Current year | 1,774 | | 2,282 |
| 1 year | 1,288.6 | | 2,282 |
| 3 years | 1,242.5 | | 2,282 |
| 5 years | 1,242.5 | | 3,408.16 |
| 10 years | 1,242.5 | | 3,408.16 |
| Manager | Title | Age | Since |
|---|---|---|---|
Luke Miels
CEO | Chief Executive Officer | - | 01/01/2026 |
Julie Brown
DFI | Director of Finance/CFO | 64 | 01/05/2023 |
| Chief Tech/Sci/R&D Officer | - | 01/12/2021 |
| Director | Title | Age | Since |
|---|---|---|---|
Luke Miels
BRD | Director/Board Member | - | 06/05/2026 |
Hal Barron
BRD | Director/Board Member | 64 | 01/01/2018 |
Jonathan Symonds
CHM | Chairman | 68 | 01/09/2019 |
| Name | Varia. Jan 1. | Weight | AuM | |
|---|---|---|---|---|
 | +6.04% | 3.15% | 27 M€ | |
| +13.09% | 2.51% | 12 M€ |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -0.72% | +0.75% | +37.68% | +27.36% | 102B | |
| -0.89% | +3.26% | +40.69% | +131.73% | 906B | |
| +0.16% | +3.73% | +57.69% | +43.55% | 555B | |
| +1.09% | +3.98% | +18.78% | +43.23% | 368B | |
| -0.94% | -0.94% | +23.89% | +10.73% | 326B | |
| -0.19% | +3.20% | +37.10% | +14.40% | 289B | |
| +0.78% | +3.09% | +30.74% | +26.23% | 285B | |
| -0.04% | +0.99% | +54.36% | -3.18% | 280B | |
| +0.91% | +1.25% | -30.88% | -49.10% | 208B | |
| -0.07% | +2.17% | +28.20% | +44.34% | 182B | |
| Average | +0.19% | +1.97% | +29.83% | +28.93% | 350.02B | |
| Weighted average by Cap. | +0.36% | +2.32% | +34.51% | +49.79% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 33.75B 45.49B 38.98B 35.64B 62.48B 4,350B 62.98B 425B 165B 2,067B 171B 167B 7,195B | 35.39B 47.7B 40.87B 37.37B 65.51B 4,561B 66.04B 446B 173B 2,167B 179B 175B 7,544B |
| Net income | 6.3B 8.49B 7.27B 6.65B 11.66B 812B 11.75B 79.36B 30.83B 386B 31.86B 31.18B 1,343B | 6.73B 9.07B 7.77B 7.1B 12.45B 867B 12.55B 84.75B 32.92B 412B 34.02B 33.3B 1,434B |
| Net Debt | 12.29B 16.56B 14.19B 12.97B 22.74B 1,584B 22.93B 155B 60.14B 752B 62.15B 60.83B 2,619B | 9.41B 12.68B 10.86B 9.93B 17.41B 1,212B 17.55B 119B 46.04B 576B 47.58B 46.57B 2,005B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 14/05/26 | 1,872.50 p | -0.72% | 3,899,742 |
| 13/05/26 | 1,886.00 p | -0.29% | 5,076,083 |
| 12/05/26 | 1,891.50 p | +2.55% | 12,115,790 |
| 11/05/26 | 1,844.50 p | +0.08% | 9,314,552 |
| 08/05/26 | 1,843.00 p | -0.83% | 6,109,465 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- GSK Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition